Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ascariasis | 11 | 2025 | 73 | 4.690 |
Why?
|
| Ascaris suum | 6 | 2025 | 32 | 3.030 |
Why?
|
| Helminths | 4 | 2022 | 47 | 2.030 |
Why?
|
| Helminthiasis | 4 | 2020 | 78 | 1.840 |
Why?
|
| Toxocariasis | 3 | 2025 | 29 | 1.760 |
Why?
|
| Anthelmintics | 3 | 2020 | 54 | 1.320 |
Why?
|
| Hypersensitivity | 3 | 2022 | 196 | 1.300 |
Why?
|
| Emigrants and Immigrants | 3 | 2020 | 157 | 1.250 |
Why?
|
| Lung Diseases | 2 | 2024 | 408 | 1.180 |
Why?
|
| Anemia | 2 | 2021 | 350 | 1.060 |
Why?
|
| Hookworm Infections | 2 | 2020 | 123 | 1.050 |
Why?
|
| Coinfection | 2 | 2020 | 188 | 1.040 |
Why?
|
| Larva | 7 | 2025 | 260 | 1.030 |
Why?
|
| Leishmaniasis | 3 | 2024 | 40 | 1.000 |
Why?
|
| Toxocara | 1 | 2025 | 12 | 0.940 |
Why?
|
| Dog Diseases | 2 | 2023 | 59 | 0.910 |
Why?
|
| Swine Diseases | 2 | 2024 | 42 | 0.880 |
Why?
|
| Host-Parasite Interactions | 2 | 2024 | 82 | 0.870 |
Why?
|
| Chitinases | 1 | 2024 | 4 | 0.860 |
Why?
|
| Cat Diseases | 1 | 2023 | 15 | 0.830 |
Why?
|
| Pandemics | 2 | 2022 | 1186 | 0.810 |
Why?
|
| Antiprotozoal Agents | 1 | 2022 | 41 | 0.770 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2022 | 49 | 0.770 |
Why?
|
| Leishmania | 1 | 2022 | 35 | 0.770 |
Why?
|
| Noncommunicable Diseases | 1 | 2022 | 21 | 0.760 |
Why?
|
| Gastric Mucosa | 1 | 2025 | 491 | 0.740 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2021 | 31 | 0.720 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2021 | 64 | 0.710 |
Why?
|
| Eosinophilia | 1 | 2022 | 105 | 0.700 |
Why?
|
| Malaria | 2 | 2024 | 99 | 0.690 |
Why?
|
| Trichinella | 1 | 2020 | 2 | 0.690 |
Why?
|
| Prednisone | 1 | 2021 | 253 | 0.690 |
Why?
|
| Trichinellosis | 1 | 2020 | 14 | 0.680 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2020 | 13 | 0.680 |
Why?
|
| Health Communication | 1 | 2020 | 31 | 0.670 |
Why?
|
| Maternal Health | 1 | 2020 | 26 | 0.670 |
Why?
|
| Travel | 1 | 2021 | 124 | 0.660 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2020 | 27 | 0.660 |
Why?
|
| Lung | 6 | 2024 | 1556 | 0.650 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 198 | 0.610 |
Why?
|
| West Nile virus | 2 | 2023 | 117 | 0.590 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 148 | 0.580 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2018 | 51 | 0.580 |
Why?
|
| Animals | 20 | 2025 | 34850 | 0.570 |
Why?
|
| West Nile Fever | 2 | 2023 | 139 | 0.570 |
Why?
|
| Giardiasis | 2 | 2017 | 10 | 0.570 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 674 | 0.560 |
Why?
|
| Zoonoses | 3 | 2025 | 52 | 0.550 |
Why?
|
| Giardia lamblia | 1 | 2017 | 10 | 0.540 |
Why?
|
| Ascaris lumbricoides | 1 | 2017 | 19 | 0.540 |
Why?
|
| Betacoronavirus | 1 | 2020 | 299 | 0.510 |
Why?
|
| Vaccination | 2 | 2020 | 1018 | 0.490 |
Why?
|
| Antiviral Agents | 1 | 2021 | 823 | 0.480 |
Why?
|
| Enterobiasis | 1 | 2015 | 4 | 0.480 |
Why?
|
| Coccidioidomycosis | 1 | 2015 | 12 | 0.470 |
Why?
|
| Meningitis, Viral | 1 | 2015 | 10 | 0.460 |
Why?
|
| Trichuriasis | 1 | 2015 | 31 | 0.460 |
Why?
|
| Humans | 32 | 2025 | 132247 | 0.460 |
Why?
|
| Encephalitis, Viral | 1 | 2015 | 21 | 0.460 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 379 | 0.450 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 390 | 0.450 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 1037 | 0.420 |
Why?
|
| United States | 10 | 2024 | 11669 | 0.410 |
Why?
|
| Ascaris | 3 | 2024 | 10 | 0.410 |
Why?
|
| Life Cycle Stages | 2 | 2025 | 26 | 0.410 |
Why?
|
| Aging | 1 | 2020 | 1254 | 0.410 |
Why?
|
| End Stage Liver Disease | 1 | 2015 | 191 | 0.390 |
Why?
|
| Disease Models, Animal | 4 | 2025 | 4690 | 0.380 |
Why?
|
| Clostridium chauvoei | 1 | 2011 | 1 | 0.370 |
Why?
|
| Enterocolitis, Neutropenic | 1 | 2011 | 2 | 0.370 |
Why?
|
| Child | 11 | 2024 | 25783 | 0.360 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 356 | 0.360 |
Why?
|
| Nervous System Diseases | 1 | 2015 | 412 | 0.340 |
Why?
|
| Public Health | 2 | 2023 | 280 | 0.320 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 293 | 0.310 |
Why?
|
| Mice, Inbred BALB C | 3 | 2021 | 1050 | 0.310 |
Why?
|
| Mice | 8 | 2025 | 18507 | 0.290 |
Why?
|
| Cost of Illness | 3 | 2022 | 286 | 0.290 |
Why?
|
| Clostridium Infections | 1 | 2011 | 249 | 0.280 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2024 | 394 | 0.280 |
Why?
|
| Immunity | 3 | 2023 | 183 | 0.240 |
Why?
|
| Toxocara canis | 1 | 2025 | 7 | 0.240 |
Why?
|
| Cats | 2 | 2023 | 118 | 0.230 |
Why?
|
| Female | 13 | 2025 | 70785 | 0.220 |
Why?
|
| Global Health | 2 | 2022 | 643 | 0.220 |
Why?
|
| Candida albicans | 2 | 2023 | 90 | 0.220 |
Why?
|
| Antimalarials | 1 | 2024 | 45 | 0.220 |
Why?
|
| Hemolysis | 1 | 2024 | 107 | 0.220 |
Why?
|
| Dogs | 2 | 2023 | 651 | 0.220 |
Why?
|
| Endemic Diseases | 2 | 2015 | 59 | 0.210 |
Why?
|
| CD11b Antigen | 1 | 2023 | 39 | 0.210 |
Why?
|
| Male | 10 | 2025 | 65012 | 0.200 |
Why?
|
| Seroepidemiologic Studies | 1 | 2023 | 144 | 0.200 |
Why?
|
| Swine | 2 | 2024 | 1179 | 0.190 |
Why?
|
| Albendazole | 2 | 2020 | 26 | 0.190 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2023 | 140 | 0.190 |
Why?
|
| Mammals | 1 | 2024 | 271 | 0.190 |
Why?
|
| Microbiota | 2 | 2024 | 434 | 0.190 |
Why?
|
| Mycoses | 1 | 2023 | 117 | 0.190 |
Why?
|
| Child, Preschool | 6 | 2024 | 14736 | 0.190 |
Why?
|
| Chagas Disease | 2 | 2024 | 308 | 0.190 |
Why?
|
| Microglia | 1 | 2023 | 138 | 0.190 |
Why?
|
| Leukocyte Count | 1 | 2022 | 249 | 0.190 |
Why?
|
| Th2 Cells | 2 | 2021 | 188 | 0.180 |
Why?
|
| Eosinophils | 1 | 2022 | 122 | 0.180 |
Why?
|
| Morbidity | 1 | 2022 | 256 | 0.180 |
Why?
|
| Stomach | 1 | 2024 | 273 | 0.180 |
Why?
|
| Iran | 1 | 2021 | 97 | 0.180 |
Why?
|
| Unemployment | 1 | 2020 | 22 | 0.170 |
Why?
|
| Ancylostomatoidea | 1 | 2020 | 60 | 0.170 |
Why?
|
| Immunomodulation | 1 | 2020 | 78 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 210 | 0.160 |
Why?
|
| Housing | 1 | 2020 | 54 | 0.160 |
Why?
|
| Candidiasis | 1 | 2021 | 137 | 0.160 |
Why?
|
| Medically Underserved Area | 1 | 2020 | 94 | 0.160 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 3761 | 0.160 |
Why?
|
| Adaptive Immunity | 1 | 2020 | 94 | 0.160 |
Why?
|
| Skin | 1 | 2022 | 527 | 0.160 |
Why?
|
| Organ Specificity | 1 | 2020 | 412 | 0.160 |
Why?
|
| Food Supply | 1 | 2020 | 93 | 0.160 |
Why?
|
| Middle Aged | 6 | 2021 | 29021 | 0.160 |
Why?
|
| Interleukin-10 | 2 | 2018 | 188 | 0.150 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 263 | 0.150 |
Why?
|
| Vaccines | 2 | 2021 | 381 | 0.150 |
Why?
|
| Ovalbumin | 1 | 2018 | 123 | 0.150 |
Why?
|
| Interleukin-5 | 1 | 2018 | 48 | 0.150 |
Why?
|
| Blood Platelets | 1 | 2021 | 323 | 0.150 |
Why?
|
| Health Education | 1 | 2020 | 235 | 0.150 |
Why?
|
| Hospitals, Pediatric | 1 | 2023 | 780 | 0.150 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2020 | 189 | 0.150 |
Why?
|
| Feces | 2 | 2024 | 753 | 0.150 |
Why?
|
| Interleukin-4 | 1 | 2018 | 146 | 0.140 |
Why?
|
| Protective Agents | 1 | 2018 | 36 | 0.140 |
Why?
|
| Cohort Studies | 2 | 2020 | 5176 | 0.140 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 149 | 0.140 |
Why?
|
| Interleukin-13 | 1 | 2018 | 94 | 0.140 |
Why?
|
| Herpesvirus 3, Human | 1 | 2018 | 30 | 0.140 |
Why?
|
| Health Policy | 1 | 2020 | 232 | 0.140 |
Why?
|
| Immunity, Innate | 1 | 2020 | 413 | 0.140 |
Why?
|
| Ecuador | 1 | 2017 | 15 | 0.140 |
Why?
|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2018 | 35 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2021 | 1233 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 902 | 0.130 |
Why?
|
| Hygiene Hypothesis | 1 | 2016 | 2 | 0.130 |
Why?
|
| Risk Factors | 2 | 2022 | 10945 | 0.130 |
Why?
|
| Interleukin-12 | 1 | 2017 | 122 | 0.130 |
Why?
|
| Poverty | 1 | 2020 | 450 | 0.130 |
Why?
|
| Interleukin-2 | 1 | 2017 | 241 | 0.130 |
Why?
|
| Onchocerca | 1 | 2015 | 6 | 0.120 |
Why?
|
| Onchocerciasis | 1 | 2015 | 22 | 0.120 |
Why?
|
| Cytokines | 1 | 2021 | 1365 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 1 | 2025 | 4758 | 0.120 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 803 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 486 | 0.120 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2015 | 68 | 0.110 |
Why?
|
| Interferon-gamma | 1 | 2017 | 539 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 666 | 0.110 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2018 | 261 | 0.110 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 464 | 0.110 |
Why?
|
| Demography | 1 | 2015 | 242 | 0.110 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 273 | 0.110 |
Why?
|
| Influenza, Human | 1 | 2020 | 700 | 0.100 |
Why?
|
| Young Adult | 2 | 2020 | 9966 | 0.100 |
Why?
|
| Gastrointestinal Tract | 1 | 2015 | 232 | 0.100 |
Why?
|
| Developing Countries | 1 | 2015 | 303 | 0.100 |
Why?
|
| Antiparasitic Agents | 1 | 2013 | 31 | 0.100 |
Why?
|
| Parasitic Diseases | 1 | 2013 | 60 | 0.090 |
Why?
|
| Taxoids | 1 | 2011 | 71 | 0.090 |
Why?
|
| Adolescent | 3 | 2020 | 20557 | 0.090 |
Why?
|
| Adult | 3 | 2020 | 31614 | 0.090 |
Why?
|
| Biomarkers | 1 | 2020 | 3404 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1500 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2011 | 376 | 0.080 |
Why?
|
| Intestines | 2 | 2024 | 606 | 0.080 |
Why?
|
| DNA, Bacterial | 1 | 2011 | 494 | 0.080 |
Why?
|
| Asthma | 1 | 2016 | 773 | 0.070 |
Why?
|
| Pregnancy | 1 | 2020 | 7557 | 0.070 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2024 | 810 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2021 | 13027 | 0.060 |
Why?
|
| Prebiotics | 1 | 2024 | 28 | 0.060 |
Why?
|
| Retrospective Studies | 1 | 2022 | 17395 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 7138 | 0.050 |
Why?
|
| Fungal Proteins | 1 | 2023 | 135 | 0.050 |
Why?
|
| Probiotics | 1 | 2024 | 226 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2023 | 234 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2023 | 826 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2021 | 98 | 0.040 |
Why?
|
| Bacteria | 1 | 2024 | 522 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 686 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 2681 | 0.040 |
Why?
|
| Antibodies, Helminth | 1 | 2018 | 125 | 0.040 |
Why?
|
| Antigens, Helminth | 1 | 2018 | 188 | 0.030 |
Why?
|
| Immunization | 1 | 2018 | 312 | 0.030 |
Why?
|
| Liver | 1 | 2024 | 1797 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 2018 | 392 | 0.030 |
Why?
|
| Aged | 1 | 2015 | 21482 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2023 | 1204 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 866 | 0.030 |
Why?
|
| Southwestern United States | 1 | 2015 | 45 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2016 | 131 | 0.030 |
Why?
|
| Infant | 2 | 2024 | 13049 | 0.030 |
Why?
|
| Dientamoebiasis | 1 | 2013 | 3 | 0.030 |
Why?
|
| Mebendazole | 1 | 2013 | 7 | 0.030 |
Why?
|
| Toxoplasmosis | 1 | 2013 | 22 | 0.020 |
Why?
|
| Cryptosporidiosis | 1 | 2013 | 44 | 0.020 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2016 | 326 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 1249 | 0.020 |
Why?
|
| Trypanosoma cruzi | 1 | 2013 | 250 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 1555 | 0.020 |
Why?
|